AstraZeneca and Bristol Myers Squibb have held preliminary merger discussions that could create one of the world's largest pharmaceutical companies, the Financial Times reported on Aug. 2, citing people familiar with the matter. The talks remain exploratory, with no agreement, transaction structure, or financial terms disclosed, and neither company has confirmed the report.
AstraZeneca carries a market capitalization of approximately GBP 196 billion (USD 264 billion), while Bristol Myers Squibb is valued at roughly USD 133 billion. A combination would produce a company with a market value approaching USD 400 billion. Strategically, the merger would combine leading franchises in oncology, cardiovascular disease, immunology, hematology, and rare diseases while significantly expanding AstraZeneca's commercial presence in the US, the world's largest pharmaceutical market.
The report revives memories of Pfizer's unsuccessful pursuit of AstraZeneca in 2014, when CEO Pascal Soriot rejected a series of takeover offers that valued the company at roughly GBP 69 billion. More than a decade later, AstraZeneca's market value has grown to nearly four times that level, potentially allowing it to pursue a transformational merger from a position of strength rather than as a takeover target.